Preview

Атеротромбоз

Расширенный поиск

НИЗКОМОЛЕКУЛЯРНЫЕ ГЕПАРИНЫ: ОРИГИНАЛЬНЫЕ ПРЕПАРАТЫ И ИХ БИОАНАЛОГИ - ВЫБОР В КЛИНИЧЕСКОЙ ПРАКТИКЕ. СЕМИНАР

Полный текст:

Аннотация

Проблема выбора препарата для профилактики и оптимальной тактики лечения артериальных и венозных тромбозов в настоящее время является одной из наиболее актуальных задач медицины. В рамках семинара, организованного журналом «Атеротромбоз», состоялось обсуждение этой важной проблемы, где, в частности, речь шла о возможности использования оригинальных низкомолекулярных гепаринов и их замены биоаналогами.

Об авторе

статья Редакционная

Россия


Список литературы

1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. ThrombHaemost, 2007, 98: 756-64.

2. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114: 489S–510S.

3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126: 188S–203S.

4. Ohman EM, Granger CG, Rice L, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. TheComplicationAfter Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. J Thromb Thrombolysis, 2005, 19: 11–9.

5. Oliveira GB, Anstrom KJ, Honeycutt EF, et al. Intravenous unfrac-tionated heparin, patient profile, and the magnitude of thrombocy-topenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH Registry (abstr). Eur Heart J, 2005, 725.

6. Hochman JS, Wali AU, Barvila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J, 1999, 138: 313–8.

7. Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem. J, 1986, 238: 329-333.

8. Holmer E, Kurachi K, Soderstrom G. The molecularweight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xia, Factor XIIa and kallikrein by antithrombin. Biochem. J, 1981, 193: 395-400.

9. Fareed J, et al. Clin Pharmacokinet, 2003, 42(12): 1043-1057.

10. Mascellani G, GuerriniM, Torri G, et al. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-β-D-glucosamine or 1,6-anhydro-β-D-mannosamine residues. Carbohydrate research, 2007, 342: 835-842.

11. Adiguzel C, Walter PJ, Hoppensteadt D, et al. Structural and functional characterization of low molecular weight heparins: impact on the developments of guidelines for generic products. Clinical and Applied Thrombosis/Hemostasis, 2009, 15(2): 137-144.

12. European Pharmacopoeia 5.3 01/2006: 1097.

13. Adiguzel C, Jeske WP, Hoppensteadt D, et al. Структурные и функциональные характеристики низкомолекулярных гепаринов в свете разработки руководств по применению генерических продуктов. Clinical and Applied Trombosis/Hemostasis, 2009 April, 15: 2.

14. Jeske W, Walenga J, Hoppensteadt D et al. Differentiating low-molecular- weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin. Thromb. Hemost., 2008, 34: 74-85.

15. Adiguzel C, Jeske W, Hoppensteadt D et al. Structural and functional characterization of low-molecularweight heparins: impact on the development of guidelines for generic products. Clin. Appl. Thromb. Hemost., 2009, 15: 137-144.

16. European Medicines Agency (EMEA). Committee for medicinal products for human use (CHMP). Cuigelines on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. (EMEA/CHMP/BMWP/118264/2007). http://www.emea.europa.eu.

17. Harenberg J, Kakkar A, Bergqvist D et al, on behalf of the subcommittee on control of anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J. Thromb. Haemost., 2009, 7: 1222-1225.

18. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the Nation’s Biosimilars Program. N Engl J Med, 2011, 365: 385-388.


Для цитирования:


НИЗКОМОЛЕКУЛЯРНЫЕ ГЕПАРИНЫ: ОРИГИНАЛЬНЫЕ ПРЕПАРАТЫ И ИХ БИОАНАЛОГИ - ВЫБОР В КЛИНИЧЕСКОЙ ПРАКТИКЕ. СЕМИНАР. Атеротромбоз. 2017;(2):142-151.

For citation:


. Atherothrombosis. 2017;(2):142-151. (In Russ.)

Просмотров: 2247


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)